

# STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2002 ALASKA

## LIST OF TABLES

### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

### FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

### FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

## **FOR DUAL ELIGIBLE BENEFICIARIES**

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

## **SUPPLEMENTAL TABLES**

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

## **APPENDIX TABLE**

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2  
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	No. of Benes							No. of Bene Mos						
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown		
<b>All</b>	<b>112,899</b>	<b>600</b>	<b>7,222</b>	<b>25,831</b>	<b>79,168</b>	<b>78</b>	<b>949,580</b>	<b>6,031</b>	<b>74,559</b>	<b>180,558</b>	<b>687,999</b>	<b>433</b>		
<b>Age</b>														
5 and younger	30,493	0	393	0	30,100	0	253,998	0	3,668	0	250,330	0		
6-14	36,648	0	757	6	35,885	0	335,753	0	8,047	23	327,683	0		
15-20	17,668	0	601	4,037	13,028	2	144,880	0	6,257	29,315	109,303	5		
21-44	21,835	0	2,362	19,274	155	44	156,836	0	24,750	131,207	683	196		
45-64	5,575	5	3,026	2,512	0	32	51,216	48	30,942	19,994	0	232		
65-74	416	333	82	1	0	0	4,356	3,458	888	10	0	0		
75-84	201	200	0	1	0	0	1,994	1,985	0	9	0	0		
85 and older	63	62	1	0	0	0	547	540	7	0	0	0		
Unknown	0	0	0	0	0	0		0	0	0	0	0		
<b>Gender</b>														
Female	62,272	384	3,717	19,532	38,561	78	514,710	3,869	39,081	135,043	336,284	433		
Male	50,625	216	3,505	6,299	40,605	0	434,854	2,162	35,478	45,515	351,699	0		
Unknown	2	0	0	0	2	0	16	0	0	0	16	0		
<b>Race</b>														
White	47,531	120	3,891	11,765	31,692	63	398,323	1,058	40,073	81,642	275,174	376		
African American	5,933	5	449	1,267	4,211	1	51,118	60	4,515	9,379	37,159	5		
Other/unknown	59,435	475	2,882	12,799	43,265	14	500,139	4,913	29,971	89,537	375,666	52		
<b>Use of Nursing Facilities<sup>c</sup></b>														
Entire year	75	18	57	0	0	0	782	199	583	0	0	0		
Part year	69	5	59	3	2	0	648	57	553	22	16	0		
None	112,755	577	7,106	25,828	79,166	78	948,150	5,775	73,423	180,536	687,983	433		
<b>Maintenance Assistance Status</b>														
Cash	41,479	573	6,567	15,548	18,791	0	356,957	5,830	67,960	118,495	164,672	0		
Medically needy	0	0	0	0	0	0		0	0	0	0	0		
Poverty-related	62,153	0	0	8,033	54,042	78	510,873	0	0	44,688	465,752	433		
Other/unknown	9,267	27	655	2,250	6,335	0	81,750	201	6,599	17,375	57,575	0		
<b>Managed Care Status</b>														
FFS all year	112,899	600	7,222	25,831	79,168	78	949,580	6,031	74,559	180,558	687,999	433		
FFS part year, with Rx claims	0	0	0	0	0	0		0	0	0	0	0		
FFS part year, no Rx claims	0	0	0	0	0	0		0	0	0	0	0		

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	No. of Benes
All	52.7 %	5.9	\$396	\$67	\$4,863	8.1 %	112,899
<b>Age</b>							
5 and younger	51.3	2.1	105	50	3,737	2.8	30,493
6-14	42.7	2.5	198	79	3,055	6.5	36,648
15-20	50.5	3.7	289	78	5,693	5.1	17,668
21-44	65.9	10.7	690	65	6,311	10.9	21,835
45-64	77.8	35.2	2,356	67	13,082	18.0	5,575
65-74	81.0	30.7	1,530	50	15,952	9.6	416
75-84	77.6	24.7	1,298	53	18,265	7.1	201
85 and older	66.7	36.6	1,500	41	23,035	6.5	63
Unknown	0.0	0.0	0	0	0	0.0	0
<b>Basis of Eligibility<sup>c</sup></b>							
Aged	77.2	29.1	1,378	47	17,086	8.1	600
Disabled	83.0	39.6	3,141	79	23,279	13.5	7,222
Adults	63.0	7.1	393	55	4,374	9.0	25,831
Children	46.4	2.3	138	59	3,243	4.3	79,168
Unknown	62.8	10.8	2,025	188	11,777	17.2	78
<b>Gender</b>							
Female	56.5	7.1	417	59	4,981	8.4	62,272
Male	48.1	4.6	371	81	4,717	7.9	50,625
Unknown	50.0	1.5	21	14	1,465	1.4	2
<b>Race</b>							
White	59.2	8.0	554	70	4,747	11.7	47,531
African American	55.2	6.5	393	60	3,669	10.7	5,933
Other/unknown	47.3	4.3	271	63	5,074	5.3	59,435
<b>Use of Nursing Facilities<sup>d</sup></b>							
Entire year	98.7	66.3	4,713	71	117,972	4.0	75
Part year	95.7	71.1	4,991	70	105,166	4.7	69
None	52.7	5.9	391	67	4,726	8.3	112,755
<b>Maintenance Assistance Status</b>							
Cash	59.6	11.3	776	69	6,348	12.2	41,479
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	47.4	2.2	133	59	3,273	4.1	62,153
Other/unknown	57.7	6.7	460	69	8,878	5.2	9,267

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
  - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:					Mean \$, All Services	Benes	Bene Mos	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less				More than 10
All	0.7	\$47	8.1 %	47.3 %	42.9 %	4.0 %	3.7 %	1.5 %	0.6 %	\$578	112,899	949,580
<b>Age</b>												
5 and younger	0.3	13	2.8	48.7	49.1	1.6	0.6	0.0	0.0	449	30,493	253,998
6-14	0.3	22	6.5	57.3	39.0	2.1	1.3	0.2	0.1	334	36,648	335,753
15-20	0.5	35	5.1	49.5	43.3	4.1	2.6	0.5	0.1	694	17,668	144,880
21-44	1.5	96	10.9	34.1	44.5	8.5	8.3	3.3	1.3	879	21,835	156,836
45-64	3.8	256	18.0	22.2	28.3	10.9	19.0	12.9	6.8	1,424	5,575	51,216
65-74	2.9	146	9.6	19.0	31.0	14.7	22.1	10.6	2.6	1,523	416	4,356
75-84	2.5	131	7.1	22.4	25.4	16.4	26.9	6.5	2.5	1,841	201	1,994
85 and older	4.2	173	6.5	33.3	19.0	14.3	19.0	7.9	6.3	2,653	63	547
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
<b>Basis of Eligibility<sup>c</sup></b>												
Aged	2.9	137	8.1	22.8	27.3	15.8	22.7	8.3	3.0	1,700	600	6,031
Disabled	3.8	304	13.5	17.0	30.5	11.7	20.1	13.1	7.6	2,255	7,222	74,559
Adults	1.0	56	9.0	37.0	45.8	7.7	6.9	2.2	0.5	626	25,831	180,558
Children	0.3	16	4.3	53.6	43.2	2.1	1.0	0.1	0.0	373	79,168	687,999
Unknown	1.9	365	17.2	37.2	26.9	14.1	17.9	3.8	0.0	2,121	78	433
<b>Gender</b>												
Female	0.9	50	8.4	43.5	44.7	4.7	4.3	1.9	0.8	603	62,272	514,710
Male	0.5	43	7.9	51.9	40.6	3.2	2.9	1.0	0.4	549	50,625	434,854
Unknown	0.2	3	1.4	50.0	50.0	0.0	0.0	0.0	0.0	183	2	16
<b>Race</b>												
White	0.9	66	11.7	40.8	45.7	5.2	5.0	2.3	0.9	567	47,531	398,323
African American	0.8	46	10.7	44.8	45.5	4.5	3.2	1.3	0.7	426	5,933	51,118
Other/unknown	0.5	32	5.3	52.7	40.3	3.0	2.7	0.9	0.4	603	59,435	500,139
<b>Use of Nursing Facilities<sup>d</sup></b>												
Entire year	6.4	452	4.0	1.3	17.3	12.0	28.0	24.0	17.3	11,315	75	782
Part year	7.6	531	4.7	4.3	10.1	8.7	26.1	27.5	23.2	11,198	69	648
None	0.7	46	8.3	47.3	42.9	4.0	3.6	1.5	0.6	562	112,755	948,150
<b>Maintenance Assistance Status</b>												
Cash	1.3	90	12.2	40.4	41.3	6.0	7.2	3.5	1.6	738	41,479	356,957
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.3	16	4.1	52.6	43.7	2.4	1.1	0.1	0.0	398	62,153	510,873
Other/unknown	0.8	52	5.2	42.3	44.3	6.1	5.2	1.6	0.5	1,006	9,267	81,750

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.5  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	No. of Rx	Rx \$	\$ per Rx	No. of Rx	Rx \$	\$ per Rx	No. of Rx	Rx \$	\$ per Rx	No. of Rx	Rx \$	\$ per Rx
<b>All</b>	<b>0.7</b>	<b>\$47</b>	<b>\$67</b>	<b>0.3</b>	<b>\$36</b>	<b>\$117</b>	<b>0.1</b>	<b>\$4</b>	<b>\$58</b>	<b>0.3</b>	<b>\$7</b>	<b>\$21</b>
<b>Age</b>												
5 and younger	0.3	13	50	0.1	9	97	0.0	1	50	0.1	2	16
6-14	0.3	22	79	0.1	17	132	0.0	2	73	0.1	3	23
15-20	0.5	35	78	0.2	28	138	0.0	3	75	0.2	5	21
21-44	1.5	96	65	0.6	73	117	0.1	7	58	0.7	16	21
45-64	3.8	256	67	1.8	198	111	0.4	19	51	1.7	39	23
65-74	2.9	146	50	1.3	110	82	0.4	14	37	1.2	22	19
75-84	2.5	131	53	1.2	99	86	0.2	10	44	1.1	22	20
85 and older	4.2	173	41	1.9	125	67	0.5	15	28	1.8	33	18
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
<b>Basis of Eligibility<sup>d</sup></b>												
Aged	2.9	137	47	1.3	101	78	0.4	13	36	1.2	23	19
Disabled	3.8	304	79	1.9	245	130	0.3	20	57	1.6	39	24
Adults	1.0	56	55	0.4	40	108	0.1	5	59	0.6	11	20
Children	0.3	16	59	0.1	12	104	0.0	2	62	0.1	2	20
Unknown	1.9	365	188	0.9	327	350	0.1	19	154	0.9	18	20
<b>Gender</b>												
Female	0.9	50	59	0.4	38	102	0.1	4	55	0.4	9	21
Male	0.5	43	81	0.2	35	144	0.0	3	64	0.2	5	22
Unknown	0.2	3	14	0.0	0	0	0.0	0	0	0.2	3	14
<b>Race</b>												
White	0.9	66	70	0.4	51	117	0.1	5	64	0.4	10	23
African American	0.8	46	60	0.4	36	97	0.1	3	58	0.3	7	20
Other/unknown	0.5	32	63	0.2	24	120	0.1	3	53	0.2	5	19
<b>Use of Nursing Facilities<sup>e</sup></b>												
Entire year	6.4	452	71	2.7	316	117	0.8	37	48	2.8	97	35
Part year	7.6	531	70	3.3	404	124	0.7	35	52	3.6	89	25
None	0.7	46	67	0.3	36	117	0.1	4	58	0.3	7	21
<b>Maintenance Assistance</b>												
<b>Status</b>												
Cash	1.3	90	69	0.6	70	119	0.1	7	55	0.6	13	22
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Poverty related	0.3	16	59	0.1	12	110	0.0	2	62	0.1	3	19
Other/unknown	0.8	52	69	0.4	40	112	0.1	5	72	0.3	8	23

Table ND5

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 5.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			Total No. of Rx	Total Rx \$	No.	As % of All Benes	No. of Bene Mos						
	Total	Patented	Off-Patent	Generic	Total	Patented						Off-Patent					
		Brand-Name	Brand-Name	Brand-Name		Brand-Name						Brand-Name					
Anti-infective Agents	0.2	0.1	0.0	0.1	\$13	\$9	\$2	\$2	\$56	\$88	\$91	\$19	81,667	\$4,582,084	36,154	32.0 %	351,962
Biologics	0.3	0.3	0.0	0.0	399	399	0	0	1251	1,255	0	43	767	959,186	266	0.2	2,406
Antineoplastic Agents	0.5	0.2	0.1	0.2	162	151	4	8	326	608	69	41	1,826	595,008	353	0.3	3,662
Endocrine/Metabolic Drugs	0.5	0.2	0.1	0.2	23	14	5	4	43	59	37	24	52,817	2,263,835	10,442	9.2	98,390
Cardiovascular Agents	1.2	0.4	0.2	0.6	42	26	6	10	36	65	37	16	61,619	2,205,303	5,200	4.6	52,354
Respiratory Agents	0.4	0.2	0.0	0.2	21	16	2	3	56	79	73	23	62,147	3,492,286	16,774	14.9	165,467
Gastrointestinal Agents	0.5	0.3	0.0	0.2	55	49	2	4	105	143	157	25	32,902	3,455,405	6,351	5.6	62,906
Genitourinary Agents	0.3	0.2	0.0	0.1	12	11	0	1	45	56	28	16	8,104	363,251	3,251	2.9	30,232
CNS Drugs	1.1	0.7	0.0	0.4	92	77	4	12	82	116	101	27	127,305	10,466,150	11,701	10.4	113,687
Stimulants/Anti-obesity/Anorexia	0.6	0.3	0.1	0.2	46	28	9	9	72	92	72	43	18,298	1,315,337	2,747	2.4	28,305
Miscellaneous Psychological/Neurological Agents	0.6	0.6	0.0	0.0	144	144	0	0	245	252	0	28	473	116,120	74	0.1	805
Analgesics and Anesthetics	0.5	0.1	0.0	0.3	33	24	2	7	62	173	53	20	100,425	6,252,448	20,396	18.1	192,236
Neuromuscular Agents	0.8	0.4	0.1	0.4	51	39	4	8	61	101	53	22	55,238	3,389,006	6,574	5.8	65,897
Nutritional Products	0.3	0.0	0.0	0.3	4	0	1	3	14	29	17	13	15,860	216,995	6,013	5.3	53,360
Hematological Agents	0.8	0.3	0.2	0.3	402	394	4	4	497	1,380	21	13	6,682	3,321,059	845	0.7	8,264
Topical Products	0.2	0.1	0.0	0.1	7	4	1	2	35	64	60	19	41,114	1,457,283	20,532	18.2	201,922
Miscellaneous Products	0.5	0.3	0.0	0.2	126	98	13	15	256	382	282	79	743	190,165	148	0.1	1,515
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	5	0	0	0	28	0	0	0	3,146	89,522	1,893	1.7	19,227
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	671,133	44,730,443	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 5.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Top 10 Drug Groups	Users				Among Users		
	Total Medicaid Rx \$	No. As % of All Benes	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo	
ANTIPSYCHOTICS	\$5,738,021	3.945	41,827	0.9	\$155	\$137	
ANALGESICS - Narcotic	4,247,678	22,110	212,508	0.3	62	20	
ANTIDEPRESSANTS	3,892,872	10,755	106,902	0.6	61	36	
ANTICONVULSANT	2,831,642	3,989	41,912	0.8	80	68	
MISC. HEMATOLOGICAL	2,645,432	183	1,889	1.0	1,386	1,400	
ULCER DRUGS	2,418,130	5,759	58,201	0.4	97	42	
ANTIASTHMATIC	2,016,593	13,519	135,759	0.3	58	15	
ANALGESICS - ANTI-INFLAMMATORY	1,479,832	11,461	110,511	0.2	56	13	
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	1,315,337	3,010	31,372	0.6	72	42	
ANTIVIRAL	1,160,278	1,230	12,104	0.4	269	96	
Total	27,745,815	75,961	752,985	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED  
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE<sup>a,b,c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANALGESICS - Narcotic			
	No. of Rx	Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>315,691</b>	<b>\$27,745,815</b>	<b>3,945</b>	<b>3.5 %</b>	<b>41,827</b>	<b>0.9</b>	<b>\$137</b>	<b>22,110</b>	<b>19.6 %</b>	<b>212,508</b>	<b>0.3</b>	<b>\$20</b>
<b>Female</b>	199,175	15,036,286	2,149	3.5	22,711	0.9	118	15,342	24.6	146,346	0.3	19
<b>Disabled</b>	93,601	8,251,120	1,033	27.8	11,568	1.2	170	2,928	78.8	32,665	0.5	42
5 and younger	418	51,834	1	0.6	12	0.5	96	12	6.7	137	0.1	1
6-14	1,973	205,626	28	10.4	321	0.7	127	45	16.8	503	0.2	7
15-20	2,105	196,196	63	28.0	684	0.8	111	62	27.6	697	0.1	2
21-44	37,666	3,312,726	490	37.7	5,542	1.2	167	1,192	91.7	13,350	0.5	38
45-64	50,872	4,422,973	450	26.6	5,000	1.3	184	1,596	94.3	17,726	0.5	48
65-74	567	61,765	1	1.9	9	0.4	41	21	40.4	252	0.5	63
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	105,574	6,785,166	1,116	1.9	11,143	0.5	64	12,414	21.2	113,681	0.3	12
5 and younger	4,056	163,213	5	0.0	60	0.3	81	381	2.6	3,888	0.1	1
6-14	13,609	825,261	204	1.2	2,157	0.6	65	1,151	6.5	12,025	0.1	2
15-20	16,149	912,007	300	3.3	3,089	0.6	68	2,342	25.4	21,823	0.2	2
21-44	57,376	3,742,466	513	3.3	4,855	0.3	52	7,627	49.8	67,011	0.4	17
45-64	11,263	909,351	66	4.5	667	0.8	89	808	55.6	7,732	0.4	25
65-74	1,999	146,921	17	7.7	204	1.2	170	58	26.4	677	0.3	14
75-84	708	57,506	7	5.6	63	0.6	107	43	34.4	478	0.3	4
85 and older	414	28,441	4	10.3	48	0.6	81	4	10.3	47	0.4	10
<b>Male</b>	116,516	12,709,529	1,796	3.5	19,116	0.9	160	6,768	13.4	66,162	0.3	22
<b>Disabled</b>	56,224	7,138,133	985	28.1	10,721	1.2	211	1,572	44.9	16,918	0.5	47
5 and younger	487	45,380	1	0.5	11	0.8	178	18	8.5	186	0.2	2
6-14	4,554	1,289,690	129	26.4	1,368	0.7	143	64	13.1	724	0.1	3
15-20	4,419	943,864	140	37.2	1,544	0.8	166	70	18.6	757	0.2	10
21-44	20,868	2,308,850	464	43.7	5,037	1.3	239	494	46.5	5,340	0.5	38
45-64	25,474	2,511,678	246	18.4	2,701	1.3	220	912	68.4	9,775	0.6	60
65-74	417	38,276	5	16.7	60	1.3	187	14	46.7	136	0.3	25
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	5	395	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	60,292	5,571,396	811	1.7	8,395	0.6	96	5,196	11.0	49,244	0.2	13
5 and younger	6,512	334,008	18	0.1	178	0.3	59	538	3.5	5,466	0.1	2
6-14	25,874	2,487,165	464	2.5	5,004	0.6	103	1,165	6.4	12,124	0.1	2
15-20	11,193	1,398,330	236	3.0	2,368	0.5	88	1,389	17.7	13,385	0.2	3
21-44	10,600	790,447	64	1.5	534	0.5	80	1,633	39.3	13,832	0.4	26
45-64	4,541	444,885	15	1.4	143	0.3	62	424	38.7	3,905	0.5	53
65-74	823	65,006	8	7.0	96	0.5	98	19	16.7	200	0.4	73
75-84	649	46,020	5	6.6	60	0.5	139	25	32.9	296	0.2	8
85 and older	100	5,535	1	4.3	12	0.7	74	3	13.0	36	0.1	1
<b>Unknown</b>	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7A

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	ANTIDEPRESSANTS					ANTICONVULSANT					MISC. HEMATOLOGICAL				
	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean Rx	Mean No. of	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean Rx	Mean No. of	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean Rx	Mean No. of
<b>All</b>	<b>10,755</b>	<b>9.5 %</b>	<b>106,902</b>	<b>0.6</b>	<b>0.6</b>	<b>3,989</b>	<b>3.5 %</b>	<b>41,912</b>	<b>0.8</b>	<b>0.8</b>	<b>183</b>	<b>0.2 %</b>	<b>1,889</b>	<b>1.0</b>	<b>\$1,400</b>
<b>Female</b>	7,753	12.5	76,295	0.6	0.6	2,426	3.9	25,432	0.8	0.8	101	0.2	1,090	0.8	67
<b>Disabled</b>	2,288	61.6	25,256	0.9	0.9	1,214	32.7	13,601	1.1	1.1	72	1.9	771	0.8	74
5 and younger	2	1.1	22	0.7	0.7	18	10.0	211	0.6	0.6	0	0.0	0	0.0	0
6-14	46	17.2	507	0.5	0.5	88	32.8	1,007	0.8	0.8	0	0.0	0	0.0	0
15-20	68	30.2	761	0.7	0.7	66	29.3	740	0.9	0.9	0	0.0	0	0.0	0
21-44	903	69.5	10,074	0.8	0.8	538	41.4	6,074	1.3	1.3	19	1.5	194	0.7	90
45-64	1,253	74.1	13,701	0.9	0.9	500	29.6	5,524	1.0	1.0	51	3.0	555	0.9	70
65-74	16	30.8	191	0.5	0.5	4	7.7	45	0.5	0.5	2	3.8	22	0.4	21
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	5,465	9.3	51,039	0.4	0.4	1,212	2.1	11,831	0.5	0.5	29	0.0	319	0.7	52
5 and younger	23	0.2	229	0.3	0.3	32	0.2	320	0.6	0.6	1	0.0	10	0.1	15
6-14	486	2.8	5,151	0.5	0.5	165	0.9	1,773	0.6	0.6	1	0.0	12	2.9	112
15-20	979	10.6	9,452	0.4	0.4	188	2.0	1,886	0.6	0.6	1	0.0	12	0.1	5
21-44	3,406	22.2	30,743	0.4	0.4	710	4.6	6,648	0.5	0.5	6	0.0	65	0.3	19
45-64	522	36.0	4,938	0.6	0.6	96	6.6	980	0.6	0.6	6	0.4	60	0.6	75
65-74	22	10.0	245	0.6	0.6	15	6.8	156	1.3	1.3	6	2.7	70	1.2	67
75-84	21	16.8	209	0.4	0.4	6	4.8	68	0.2	0.2	6	4.8	66	0.4	48
85 and older	6	15.4	72	1.2	1.2	0	0.0	0	0.0	0.0	2	5.1	24	0.8	55
<b>Male</b>	3,002	5.9	30,607	0.6	0.6	1,563	3.1	16,480	0.9	0.9	82	0.2	799	1.3	3,219
<b>Disabled</b>	1,141	32.6	12,330	0.9	0.9	846	24.1	9,227	1.1	1.1	56	1.6	547	1.1	2,270
5 and younger	2	0.9	23	0.5	0.5	22	10.3	223	0.6	0.6	0	0.0	0	0.0	0
6-14	88	18.0	980	0.6	0.6	139	28.4	1,527	0.8	0.8	1	0.2	10	11.9	78,403
15-20	116	30.9	1,279	0.6	0.6	117	31.1	1,295	0.9	0.9	2	0.5	23	2.4	18,545
21-44	392	36.9	4,202	1.1	1.1	310	29.2	3,390	1.3	1.3	3	0.3	36	0.2	48
45-64	530	39.7	5,706	0.8	0.8	253	19.0	2,740	1.1	1.1	47	3.5	454	0.9	63
65-74	13	43.3	140	0.6	0.6	5	16.7	52	0.8	0.8	3	10.0	24	0.3	32
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	1,861	3.9	18,277	0.5	0.5	717	1.5	7,253	0.6	0.6	26	0.1	252	1.7	5,279
5 and younger	22	0.1	204	0.3	0.3	43	0.3	442	0.5	0.5	1	0.0	10	1.2	4,324
6-14	720	3.9	7,571	0.5	0.5	340	1.9	3,635	0.7	0.7	4	0.0	32	4.6	19,946
15-20	542	6.9	5,324	0.4	0.4	155	2.0	1,550	0.5	0.5	3	0.0	26	5.2	23,983
21-44	434	10.5	3,733	0.4	0.4	127	3.1	1,089	0.4	0.4	3	0.1	19	0.4	132
45-64	122	11.1	1,201	0.5	0.5	35	3.2	338	0.6	0.6	8	0.7	82	0.4	182
65-74	11	9.6	127	0.7	0.7	10	8.8	115	1.4	1.4	3	2.6	35	0.7	78
75-84	8	10.5	94	1.3	1.3	7	9.2	84	0.6	0.6	4	5.3	48	1.6	107
85 and older	2	8.7	23	2.3	2.3	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0
<b>Unknown</b>	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0

Table ND7B

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.7C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	ULCER DRUGS				ANTI-ASTHMATIC				ANALGESICS - ANTI-INFLAMMATORY						
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>5,759</b>	<b>5.1 %</b>	<b>58,201</b>	<b>0.4</b>	<b>\$42</b>	<b>13,519</b>	<b>12.0 %</b>	<b>135,759</b>	<b>0.3</b>	<b>\$15</b>	<b>11,461</b>	<b>10.2 %</b>	<b>110,511</b>	<b>0.2</b>	<b>\$13</b>
<b>Female</b>	3,985	6.4	40,411	0.4	42	7,754	12.5	77,455	0.3	15	8,050	12.9	77,061	0.3	15
<b>Disabled</b>	1,377	37.0	15,438	0.7	64	1,578	42.5	17,646	0.4	26	1,551	41.7	17,342	0.4	35
5 and younger	18	10.0	205	0.3	24	50	27.8	538	0.3	23	5	2.8	55	0.1	1
6-14	23	8.6	269	0.5	47	53	19.8	608	0.2	16	10	3.7	106	0.2	3
15-20	29	12.9	329	0.4	39	36	16.0	398	0.2	11	36	16.0	389	0.1	2
21-44	428	32.9	4,823	0.6	59	482	37.1	5,496	0.3	20	605	46.5	6,915	0.4	28
45-64	849	50.2	9,471	0.7	70	928	54.8	10,326	0.4	31	876	51.8	9,657	0.5	40
65-74	30	57.7	341	0.4	43	29	55.8	280	0.3	14	19	36.5	220	0.5	81
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	2,608	4.5	24,973	0.3	29	6,176	10.5	59,809	0.2	12	6,499	11.1	59,719	0.2	9
5 and younger	138	0.9	1,277	0.2	12	1,583	10.9	15,390	0.2	7	209	1.4	2,034	0.1	2
6-14	208	1.2	2,218	0.2	14	1,470	8.4	15,276	0.2	12	486	2.8	4,887	0.1	4
15-20	371	4.0	3,644	0.2	17	855	9.3	8,325	0.2	13	1,390	15.1	13,136	0.2	5
21-44	1,454	9.5	13,479	0.3	30	1,833	12.0	16,440	0.3	14	3,772	24.6	33,327	0.2	9
45-64	318	21.9	3,009	0.4	44	311	21.4	3,011	0.4	22	539	37.1	5,147	0.3	18
65-74	73	33.2	823	0.5	48	85	38.6	938	0.4	22	68	30.9	789	0.5	29
75-84	33	26.4	368	0.5	59	31	24.8	333	0.3	26	27	21.6	305	0.4	30
85 and older	13	33.3	155	1.0	89	8	20.5	96	0.3	25	8	20.5	94	0.8	31
<b>Male</b>	1,774	3.5	17,790	0.4	40	5,765	11.4	58,304	0.2	14	3,411	6.7	33,450	0.2	11
<b>Disabled</b>	724	20.7	7,863	0.6	54	791	22.6	8,812	0.4	30	786	22.4	8,508	0.4	25
5 and younger	15	7.0	165	0.3	23	69	32.4	772	0.2	19	6	2.8	59	0.1	2
6-14	43	8.8	478	0.5	58	115	23.5	1,281	0.3	35	14	2.9	141	0.1	3
15-20	42	11.2	463	0.5	47	63	16.8	724	0.4	22	40	10.6	438	0.2	5
21-44	171	16.1	1,907	0.6	47	119	11.2	1,330	0.3	17	243	22.9	2,644	0.3	24
45-64	441	33.1	4,714	0.6	58	417	31.3	4,609	0.5	36	467	35.0	5,050	0.4	29
65-74	12	40.0	136	0.6	70	8	26.7	96	0.4	32	16	53.3	176	0.3	20
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	1,050	2.2	9,927	0.3	29	4,974	10.6	49,492	0.2	12	2,625	5.6	24,942	0.2	6
5 and younger	184	1.2	1,619	0.2	15	2,319	14.9	22,616	0.2	9	287	1.8	2,830	0.1	2
6-14	166	0.9	1,748	0.2	16	1,757	9.6	18,228	0.2	13	471	2.6	4,833	0.1	2
15-20	163	2.1	1,647	0.2	21	510	6.5	4,921	0.2	15	789	10.1	7,660	0.1	4
21-44	346	8.3	3,023	0.3	36	223	5.4	2,007	0.3	14	803	19.3	6,919	0.2	10
45-64	145	13.2	1,358	0.4	45	98	8.9	963	0.5	31	232	21.1	2,223	0.2	14
65-74	26	22.8	292	0.5	37	39	34.2	443	0.4	25	28	24.6	300	0.3	17
75-84	18	23.7	216	0.8	63	23	30.3	254	0.4	25	12	15.8	141	0.3	23
85 and older	2	8.7	24	0.5	62	5	21.7	60	0.3	15	3	13.0	36	0.2	12
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C  
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY, BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	STIMULANTS/ANTI-OBESITY/ANOREXIANTS				ANTIVIRAL							
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Benes	No. of Bene Mos
<b>All</b>	<b>3,010</b>	<b>2.7 %</b>	<b>31,372</b>	<b>0.6</b>	<b>\$42</b>	<b>1,230</b>	<b>1.1 %</b>	<b>12,104</b>	<b>0.4</b>	<b>\$96</b>	<b>112,899</b>	<b>949,580</b>
<b>Female</b>	856	1.4	8,898	0.6	42	876	1.4	8,542	0.3	76	62,272	514,710
<b>Disabled</b>	110	3.0	1,218	0.7	62	190	5.1	2,144	0.5	139	3,717	39,081
5 and younger	1	0.6	12	0.1	6	2	1.1	22	0.1	3	180	1,636
6-14	35	13.1	378	0.8	55	4	1.5	45	0.3	20	268	2,875
15-20	12	5.3	137	0.5	35	3	1.3	28	0.2	7	225	2,325
21-44	28	2.2	315	0.7	79	105	8.1	1,216	0.6	140	1,300	14,005
45-64	34	2.0	376	0.5	66	76	4.5	833	0.3	153	1,692	17,674
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	52	566
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	746	1.3	7,680	0.6	39	686	1.2	6,398	0.3	55	58,555	475,629
5 and younger	14	0.1	150	0.4	23	51	0.3	530	0.1	5	14,582	121,098
6-14	507	2.9	5,376	0.5	36	94	0.5	984	0.1	7	17,590	160,746
15-20	120	1.3	1,172	0.5	39	113	1.2	1,064	0.2	23	9,225	74,270
21-44	93	0.6	869	0.7	58	385	2.5	3,390	0.3	54	15,322	103,980
45-64	12	0.8	113	0.9	47	41	2.8	406	0.9	335	1,452	11,661
65-74	0	0.0	0	0.0	0	2	0.9	24	0.1	7	220	2,288
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	125	1,236
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	39	350
<b>Male</b>	2,154	4.3	22,474	0.6	42	354	0.7	3,562	0.5	143	50,625	434,854
<b>Disabled</b>	202	5.8	2,229	0.7	56	153	4.4	1,545	0.8	271	3,505	35,478
5 and younger	9	4.2	88	0.6	30	3	1.4	33	0.3	10	213	2,032
6-14	114	23.3	1,259	0.7	55	6	1.2	70	0.2	6	489	5,172
15-20	51	13.6	576	0.7	58	6	1.6	70	0.1	29	376	3,932
21-44	10	0.9	105	0.6	67	68	6.4	646	0.9	245	1,062	10,745
45-64	18	1.3	201	0.8	59	70	5.2	726	0.9	354	1,334	13,268
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	30	322
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	1,952	4.1	20,245	0.6	40	201	0.4	2,017	0.2	45	47,120	399,376
5 and younger	92	0.6	965	0.4	25	48	0.3	508	0.1	5	15,516	129,216
6-14	1,534	8.4	15,989	0.6	40	72	0.4	741	0.1	9	18,301	166,960
15-20	295	3.8	3,020	0.6	44	34	0.4	355	0.2	65	7,842	64,353
21-44	27	0.7	231	0.6	47	35	0.8	313	0.3	98	4,151	28,106
45-64	4	0.4	40	0.8	107	12	1.1	100	0.5	286	1,097	8,613
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	114	1,180
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	76	758
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	23	190
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	16

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
<b>All</b>	<b>\$452</b>	<b>6.4</b>	<b>75</b>	<b>782</b>
<b>Age</b>				
0-64	501	6.9	54	547
65-74	349	5.4	12	130
75-84	306	3.9	6	69
85 and older	361	6.7	3	36
Unknown	0	0.0	0	0
<b>Gender</b>				
Female	490	6.7	48	521
Male	377	5.7	27	261
Unknown	0	0.0	0	0
<b>Race</b>				
White	571	7.9	30	295
African American	323	4	2	24
Other/unknown	383	5.5	43	463
<b>Basis of Eligibility<sup>c</sup></b>				
Aged	326	4.5	18	199
Disabled	495	7.0	57	583
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2002 Medicaid enrollment. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			Total # of Rx	Total Rx \$	No.	As % of All-Year NF Residents	No. of Bene Mos						
	Total	Patented	Off-Patent	Total	Patented	Off-Patent											
	Brand-Name	Brand-Name	Generic	Brand-Name	Brand-Name	Generic											
Anti-infective Agents	0.4	0.2	0.0	0.2	\$25	\$20	\$1	\$4	\$63	\$102	\$22	207	\$13,006	48	64.0 %	520	
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0.0	0	
Antineoplastic Agents	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0.0	0	
Endocrine/Metabolic Drugs	1.4	0.6	0.3	0.5	85	48	14	23	60	74	47	48	387	23,181	24	32.0	273
Cardiovascular Agents	1.8	0.5	0.4	1.0	76	37	18	21	41	78	44	22	796	32,855	41	54.7	433
Respiratory Agents	0.6	0.3	0.1	0.2	34	24	5	5	60	75	66	30	187	11,266	30	40.0	332
Gastrointestinal Agents	1.3	0.7	0.0	0.5	93	76	1	16	74	104	114	30	639	47,132	48	64.0	505
Genitourinary Agents	0.3	0.3	0.0	0.0	25	23	0	2	80	86	63	41	60	4,827	17	22.7	191
CNS Drugs	1.8	1.3	0.0	0.5	156	130	9	18	87	102	235	37	976	84,947	51	68.0	543
Stimulants/Anti-obesity/Anorexia	1.4	0.0	0.0	1.4	35	0	0	35	26	0	0	26	37	945	3	4.0	27
Miscellaneous Psychological/Neurological Agents	0.3	0.3	0.0	0.0	51	51	0	0	161	161	0	0	12	1,932	4	5.3	38
Analgesics and Anesthetics	1.0	0.4	0.2	0.5	71	51	6	13	73	141	42	29	436	31,865	41	54.7	450
Neuromuscular Agents	1.1	0.2	0.2	0.7	76	24	8	45	71	106	45	65	472	33,300	39	52.0	437
Nutritional Products	0.8	0.0	0.0	0.7	17	0	1	16	23	0	35	22	159	3,580	20	26.7	212
Hematological Agents	1.8	0.3	1.0	0.5	336	309	19	9	188	898	19	18	224	42,003	13	17.3	125
Topical Products	0.8	0.3	0.0	0.5	49	31	2	16	64	120	45	34	304	19,577	35	46.7	401
Miscellaneous Products	0.9	0.0	0.0	0.9	89	0	0	89	97	0	0	97	11	1,072	1	1.3	12
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	9	0	0	0	29	0	0	0	68	1,973	18	24.0	210
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	4,975	353,461	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003). In Alaska, 5.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Top 10 Drug Groups in Nursing Facilities	Users				Among Users		
	Total Medicaid Rx \$	No. of Users	As % of All-Year NF Residents	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$44,337	28	37.3 %	308	0.8	\$181	\$144
ULCER DRUGS	40,123	47	62.7	501	0.8	97	80
ANTIDEPRESSANTS	35,234	47	62.7	520	1.1	64	68
ANTICONVULSANT	25,680	36	48.0	391	0.7	89	66
ANTICOAGULANTS	24,596	10	13.3	110	1.6	143	224
HEMATOPOIETIC AGENTS	16,260	10	13.3	76	1.0	214	214
ANALGESICS - Narcotic	18,962	39	52.0	422	0.6	77	45
DERMATOLOGICAL	17,559	56	74.7	629	0.4	76	28
ANTIIDIABETIC	15,390	27	36.0	279	0.9	62	55
ANTIHYPERTENSIVE	13,421	32	42.7	314	1.0	45	43
Total	251,562	332		3,550	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup> NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ULCER DRUGS				
	No. of Rx	Rx \$	No. of Users	Mean No. of Rx	Users as % of All-Year NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All-Year NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>2,770</b>	<b>\$251,562</b>	<b>28</b>	<b>0.8</b>	<b>37.3 %</b>	<b>308</b>	<b>0.8</b>	<b>\$144</b>	<b>47</b>	<b>62.7 %</b>	<b>501</b>	<b>0.8</b>	<b>\$80</b>
<b>Female</b>	1,843	184,365	14	0.8	29.2	166	0.8	162	28	58.3	314	0.8	74
<b>Disabled</b>	1,462	145,453	6	0.5	16.7	72	0.5	114	19	52.8	209	0.8	63
64 or younger	1,438	144,130	6	0.5	17.1	72	0.5	114	19	54.3	209	0.8	63
65-74	24	1,323	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	381	38,912	8	1.0	66.7	94	1.0	198	9	75.0	105	0.9	97
64 or younger	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	209	23,032	4	1.3	66.7	48	1.3	259	4	66.7	46	1.0	130
75-84	51	7,245	4	0.7	133.3	46	0.7	135	1	33.3	11	0.1	9
85 and older	121	8,635	0	0.0	0.0	0	0.0	0	4	133.3	48	0.9	86
<b>Male</b>	927	67,197	14	0.8	51.9	142	0.8	123	19	70.4	187	0.9	90
<b>Disabled</b>	766	55,571	11	0.9	52.4	106	0.9	137	16	76.2	154	0.9	86
64 or younger	582	45,834	10	0.8	52.6	94	0.8	136	14	73.7	130	0.9	90
65-74	184	9,737	1	1.9	50.0	12	1.9	144	2	100.0	24	0.7	60
75-84	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	161	11,626	3	0.5	50.0	36	0.5	84	3	50.0	33	0.9	110
64 or younger	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	51	3,290	0	0.0	0.0	0	0.0	0	2	66.7	21	0.8	89
75-84	110	8,336	3	0.5	100.0	36	0.5	84	1	33.3	12	1.2	149
85 and older	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Unknown</b>	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	ANTIDEPRESSANTS						ANTICONVULSANT						ANTICOAGULANTS							
	Users as %			Users as %			Users as %			Users as %			Users as %			Users as %				
	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx		
<b>All</b>	47	62.7 %	\$68	1.1	520	1.1	\$68	1.1	36	48.0 %	0.7	\$66	0.7	391	0.7	10	13.3 %	110	1.6	\$224
<b>Female</b>	29	60.4	74	1.1	336	1.1	74	1.1	22	45.8	0.8	76	0.8	239	0.8	8	16.7	91	1.5	260
<b>Disabled</b>	23	63.9	86	1.3	266	1.3	86	1.3	17	47.2	0.9	93	0.9	184	0.9	4	11.1	43	2.7	502
64 or younger	22	62.9	88	1.3	254	1.3	88	1.3	17	48.6	0.9	93	0.9	184	0.9	4	11.4	43	2.7	502
65-74	1	100.0	47	0.7	12	0.7	47	0.7	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	6	50.0	29	0.5	70	0.5	29	0.5	5	41.7	0.5	17	0.5	55	0.5	4	33.3	48	0.5	44
64 or younger	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
65-74	2	33.3	30	0.4	22	0.4	30	0.4	3	50.0	0.8	26	0.8	32	0.8	0	0.0	0	0.0	0
75-84	2	66.7	25	0.4	24	0.4	25	0.4	2	66.7	0.1	5	0.1	23	0.1	0	0.0	0	0.0	0
85 and older	2	66.7	33	0.7	24	0.7	33	0.7	0	0.0	0.0	0	0.0	0	0.0	4	133.3	48	0.5	44
<b>Male</b>	18	66.7	56	1.0	184	1.0	56	1.0	14	51.9	0.7	50	0.7	152	0.7	2	7.4	19	1.7	48
<b>Disabled</b>	11	52.4	68	1.3	105	1.3	68	1.3	11	52.4	0.7	61	0.7	116	0.7	2	9.5	19	1.7	48
64 or younger	10	52.6	66	1.3	93	1.3	66	1.3	10	52.6	0.6	65	0.6	104	0.6	1	5.3	7	1.1	40
65-74	1	50.0	86	1.1	12	1.1	86	1.1	1	50.0	1.1	23	1.1	12	1.1	1	50.0	12	2.0	53
75-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	7	116.7	39	0.6	79	0.6	39	0.6	3	50.0	0.7	16	0.7	36	0.7	0	0.0	0	0.0	0
64 or younger	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
65-74	3	100.0	37	0.8	33	0.8	37	0.8	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
75-84	4	133.3	40	0.5	46	0.5	40	0.5	3	100.0	0.7	16	0.7	36	0.7	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
<b>Unknown</b>	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	HEMATOPOIETIC AGENTS					ANALGESICS - Narcotic					DERMATOLOGICAL				
	Users as %					Users as %					Users as %				
	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx
<b>All</b>	10	76	1.0	\$214	0.6	39	422	0.6	\$45	56	629	0.4	\$28	0.4	\$28
<b>Female</b>	5	28	0.7	559	0.7	25	283	0.7	60	35	399	0.4	35	0.4	35
<b>Disabled</b>	5	28	0.7	559	0.8	24	271	0.8	63	28	319	0.4	40	0.4	40
64 or younger	5	28	0.7	559	0.8	23	259	0.8	65	27	307	0.5	42	0.5	42
65-74	0	0	0.0	0	0.1	1	12	0.1	1	1	12	0.2	2	0.2	2
75-84	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
85 and older	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	0	0	0.0	0	0.0	1	12	0.1	1	7	80	0.2	15	0.2	15
64 or younger	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
65-74	0	0	0.0	0	0.0	0	0	0.0	0	4	44	0.2	15	0.2	15
75-84	0	0	0.0	0	0.1	1	12	0.1	1	0	0	0.0	0	0.0	0
85 and older	0	0	0.0	0	0.0	0	0	0.0	0	3	36	0.2	14	0.2	14
<b>Male</b>	5	48	1.2	13	0.3	14	139	0.3	15	21	230	0.3	16	0.3	16
<b>Disabled</b>	5	48	1.2	13	0.3	12	115	0.3	17	12	132	0.4	21	0.4	21
64 or younger	4	36	1.3	14	0.4	11	103	0.4	19	9	96	0.3	22	0.3	22
65-74	1	12	0.9	11	0.1	1	12	0.1	1	3	36	0.6	18	0.6	18
75-84	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
85 and older	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	0	0	0.0	0	0.0	2	24	0.1	1	9	98	0.2	9	0.2	9
64 or younger	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
65-74	0	0	0.0	0	0.0	0	0	0.0	0	2	18	0.2	4	0.2	4
75-84	0	0	0.0	0	0.1	2	24	0.1	1	7	80	0.3	10	0.3	10
85 and older	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0
<b>Unknown</b>	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	ANTIDIABETIC					ANTIHYPERTENSIVE					Mean Rx \$	All-Year NF Residents	Bene Mos among All-Year NF Residents
	Users as %		No. of Bene Mos among Users		Mean No. of Rx	Users as %		No. of Bene Mos among Users		Mean No. of Rx			
	No. of Users	Residents	No. of Users	Residents		No. of Users	Residents	No. of Users	Residents				
<b>All</b>	<b>27</b>	<b>36.0 %</b>	<b>279</b>	<b>0.9</b>	<b>\$55</b>	<b>32</b>	<b>42.7 %</b>	<b>314</b>	<b>1.0</b>	<b>\$43</b>	<b>75</b>	<b>782</b>	
<b>Female</b>	17	35.4	200	0.9	59	18	37.5	207	1.0	45	48	521	
<b>Disabled</b>	12	33.3	140	1.0	71	12	33.3	137	1.1	52	36	380	
64 or younger	12	34.3	140	1.0	71	11	31.4	125	1.1	52	35	368	
65-74	0	0.0	0	0.0	0	1	100.0	12	1.1	61	1	12	
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
<b>Other Eligibles</b>	5	41.7	60	0.7	29	6	50.0	70	0.8	30	12	141	
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
65-74	2	33.3	24	1.0	50	4	66.7	46	0.7	28	6	70	
75-84	2	66.7	24	0.3	10	0	0.0	0	0.0	0	3	35	
85 and older	1	33.3	12	0.8	23	2	66.7	24	0.9	34	3	36	
<b>Male</b>	10	37.0	79	0.8	47	14	51.9	107	0.9	39	27	261	
<b>Disabled</b>	8	38.1	64	0.9	55	13	61.9	95	0.9	41	21	203	
64 or younger	5	26.3	28	1.0	47	11	57.9	71	0.8	32	19	179	
65-74	3	150.0	36	0.8	61	2	100.0	24	1.4	69	2	24	
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
<b>Other Eligibles</b>	2	33.3	15	0.3	10	1	16.7	12	0.9	21	6	58	
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
65-74	1	33.3	3	1.3	41	0	0.0	0	0.0	0	3	24	
75-84	1	33.3	12	0.1	3	1	33.3	12	0.9	21	3	34	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0	

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 69 beneficiaries who were in nursing facilities for part of their enrollment and their 648 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mdadb.asp](http://www.Medi-Span.com/products/product_mdadb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11  
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 ALASKA, 2002

Beneficiary Characteristics	No. of Benes with at Least One Part D Excl Rx	% Benes with at Least One Part D Excl Rx	No. of Part D Excl Rx per Bene	Total No. Part D Excl Rx	Part D Excl Rx \$ per Bene	Total Part D Excl Rx \$	\$ per Part D Excl Rx	Part D Excl Rx \$ as % of All Nonduals Rx \$	Total No. of Benes
<b>Age</b>									
5 and younger	1,840	6.0	0.1	3,948	5	150,582	38	4.7	30,493
6-14	1,091	3.0	0.1	2,361	8	276,023	117	3.8	36,648
15-20	1,001	5.7	0.1	2,157	8	132,730	62	2.6	17,668
21-44	3,165	14.5	0.5	11,683	19	413,866	35	2.7	21,835
45-64	1,336	24.0	1.6	8,705	78	435,398	50	3.3	5,575
65-74	53	12.7	0.7	308	32	13,135	43	2.1	416
75-84	25	12.4	0.8	153	51	10,178	67	3.9	201
85 and older	8	12.7	0.8	52	67	4,201	81	4.4	63
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
<b>Basis of Eligibility<sup>c</sup></b>									
Aged	72	12.0	0.7	444	42	25,259	57	3.1	600
Disabled	1,948	27.0	1.8	12,889	122	884,476	69	3.9	7,222
Adults	3,140	12.2	0.4	9,639	9	242,371	25	2.4	25,831
Children	3,339	4.2	0.1	6,282	3	270,531	43	2.5	79,168
Unknown	20	25.6	1.4	113	173	13,476	119	8.5	78
<b>Gender</b>									
Female	5,679	9.1	0.3	19,882	14	843,065	42	3.2	62,272
Male	2,840	5.6	0.2	9,485	12	593,048	63	3.2	50,625
Unknown	0	0.0	0.0	0	0	0	0	0.0	2
<b>Race</b>									
White	3,993	8.4	0.4	17,279	18	869,396	50	3.3	47,531
African American	399	6.7	0.2	1,108	5	31,226	28	1.3	5,933
Other/unknown	4,127	6.9	0.2	10,980	9	535,491	49	3.3	59,435
<b>Use of Nursing Facilities<sup>d</sup></b>									
Entire year	40	53.3	2.7	206	169	12,682	62	3.6	75
Part year	39	56.5	4.8	332	345	23,797	72	6.9	69
None	8,440	7.5	0.3	28,829	12	1,399,634	49	3.2	112,755
<b>Maintenance Assistance Status</b>									
Cash	4,978	12.0	0.5	22,024	25	1,039,660	47	3.2	41,479
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	2,756	4.4	0.1	4,953	4	221,398	45	2.7	62,153
Other/unknown	785	8.5	0.3	2,390	19	175,055	73	4.1	9,267

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 ALASKA, 2002

Beneficiary Characteristics	No. Rx per Bene Mo.	Rx \$ per Bene Mo.	\$ per Rx	Barbiturate \$ per Bene Mo.	Benzodiazepine \$ per Bene Mo.	No. of Bene Mos
All	0.0	\$2	\$49	\$0	\$0	949,580
<b>Age</b>						
5 and younger	0.0	1	38	0	0	253,998
6-14	0.0	1	117	0	0	335,753
15-20	0.0	1	62	0	0	144,880
21-44	0.1	3	35	0	1	156,836
45-64	0.2	9	50	0	2	51,216
65-74	0.1	3	43	0	1	4,356
75-84	0.1	5	67	0	0	1,994
85 and older	0.1	8	81	0	2	547
Unknown	0.0	0	0	0	0	0
<b>Basis of Eligibility<sup>c</sup></b>						
Aged	0.1	4	57	0	1	6,031
Disabled	0.2	12	69	0	2	74,559
Adults	0.1	1	25	0	0	180,558
Children	0.0	0	43	0	0	687,999
Unknown	0.3	31	119	0	2	433
<b>Gender</b>						
Female	0.0	2	42	0	0	514,710
Male	0.0	1	63	0	0	434,854
Unknown	0.0	0	0	0	0	16
<b>Race</b>						
White	0.0	2	50	0	0	398,323
African American	0.0	1	28	0	0	51,118
Other/unknown	0.0	1	49	0	0	500,139
<b>Use of Nursing Facilities<sup>d</sup></b>						
Entire year	0.3	16	62	0	8	782
Part year	0.5	37	72	0	5	648
None	0.0	1	49	0	0	948,150
<b>Maintenance Assistance Status</b>						
Cash	0.1	3	47	0	1	356,957
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	0	45	0	0	510,873
Other/unknown	0.0	2	73	0	0	81,750

Table ND12

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
  - b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
  - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.13  
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
FOR SELECTED DRUG CATEGORIES AMONG NONDUALS<sup>a,b,c</sup>  
ALASKA, 2002

Drug Category	No. Users	Rx \$ per User	Total Rx \$	Rx \$ as % of All Part D Excl Rx \$	Total No. Rx.	\$ per Rx	No. Rx as % of All Part D Excl Rx
<b>All</b>	<b>9,294</b>	<b>\$155</b>	<b>\$1,436,113</b>	<b>100.0 %</b>	<b>29,367</b>	<b>\$49</b>	<b>100.0 %</b>
Anorexia or weight loss/gain	658	161	106,117	7.4	1,199	89	4.1
Fertility drugs	19	82	1,551	0.1	21	74	0.1
Drugs for cosmetic purposes	202	1,272	256,990	17.9	951	270	3.2
Cough and cold medications	832	222	184,963	12.9	1,433	129	4.9
Vitamins and minerals	5	34,157	170,787	11.9	51	3,349	0.2
Non-prescription drugs	3,786	101	383,420	26.7	8,621	44	29.4
Barbiturates	356	19	6,863	0.5	440	16	1.5
Benzodiazepines	3,425	78	267,285	18.6	16,595	16	56.5
Other Part D Excl Rx Drugs	11	5,285	58,137	4.0	56	1,038	0.2

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2002. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup>  
NONDUAL BENEFICIARIES, ALASKA, 2002

Beneficiary Characteristics	No. of Benes					No. of Bene Mos					
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown
<b>All</b>	<b>112,899</b>	<b>600</b>	<b>7,222</b>	<b>25,831</b>	<b>79,168</b>	<b>78</b>	<b>6,031</b>	<b>74,559</b>	<b>180,558</b>	<b>687,999</b>	<b>433</b>
<b>Age</b>											
5 and younger	30,493	0	393	0	30,100	0	0	3,668	0	250,330	0
6-14	36,648	0	757	6	35,885	0	0	8,047	23	327,683	0
15-20	17,668	0	601	4,037	13,028	2	0	6,257	29,315	109,303	5
21-44	21,835	0	2,362	19,274	155	44	0	24,750	131,207	683	196
45-64	5,575	5	3,026	2,512	0	32	48	30,942	19,994	0	232
65-74	416	333	82	1	0	0	3,458	888	10	0	0
75-84	201	200	0	1	0	0	1,985	0	9	0	0
85 and older	63	62	1	0	0	0	540	7	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0
<b>Gender</b>											
Female	62,272	384	3,717	19,532	38,561	78	3,869	39,081	135,043	336,284	433
Male	50,625	216	3,505	6,299	40,605	0	2,162	35,478	45,515	351,699	0
Unknown	2	0	0	0	2	0	0	0	0	16	0
<b>Race</b>											
White	47,531	120	3,891	11,765	31,692	63	1,058	40,073	81,642	275,174	376
African American	5,933	5	449	1,267	4,211	1	60	4,515	9,379	37,159	5
Other/unknown	59,435	475	2,882	12,799	43,265	14	4,913	29,971	89,537	375,666	52
<b>Use of Nursing Facilities<sup>c</sup></b>											
Entire year	75	18	57	0	0	0	199	583	0	0	0
Part year	69	5	59	3	2	0	57	553	22	16	0
None	112,755	577	7,106	25,828	79,166	78	5,775	73,423	180,536	687,983	433
<b>Maintenance Assistance Status</b>											
Cash	41,479	573	6,567	15,548	18,791	0	5,830	67,960	118,495	164,672	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0
Poverty related	62,153	0	0	8,033	54,042	78	0	0	44,688	465,752	433
Other/unknown	9,267	27	655	2,250	6,335	0	201	6,599	17,375	57,575	0
<b>Managed Care Status</b>											
FFS all year	112,899	600	7,222	25,831	79,168	78	6,031	74,559	180,558	687,999	433
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
  - b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
  - c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2  
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2002

	Bene Mos in Cell J of Table 1		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
<b>All</b>	<b>112,899</b>	<b>949,580</b>	<b>112,899</b>	<b>949,580</b>	<b>0</b>	<b>0</b>
FFS all year	112,899	949,580	112,899	949,580	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2002 file for Alaska, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.